SBIR/STTR Research Award
THE OVERALL OBJECTIVE OF THIS RESEARCH IS TO EVALUATE THE POTENTIAL EFFICACY OF HORMONOCONJUGATE THERAPY FOR MELANOMA.
Award amount
$50,000Program and phase
SBIR · Phase IAward year
1986Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Not reported
- Recipient company
- Piedmont Research Company
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
THE OVERALL OBJECTIVE OF THIS RESEARCH IS TO EVALUATE THE POTENTIAL EFFICACY OF HORMONOCONJUGATE THERAPY FOR MELANOMA.RESEARCHERS WILL CONJUGATE SEVERAL DIFFERENT PROTEINS OR OR PEPTIDES TO THE HORMONE MSH AND ATTEMPT TO DELIVER THESE TO MURINE B16 MELANOMA. THE GOAL IS TO USE MSH AS A VEHICLEFOR DELIVERING AN IMMUNOGENIC MOLECULE TO THE B16 CELL MEMBRANE, THEREBY PROVIDING A TARGET FOR IMMUNE DESTRUCTION OF THE TUMOR CELLS. TO ACCOMPLISH THIS, THE CONJUGATES WILLBE SYNTHESIZED AND THEIR ACTIVITY EXAMINED IN VITRO. CONJUGATES THAT RETAIN RECEPTOR BINDING ACTIVITY WILL NEXT BE EVALUATED FOR THEIR IMMUNOGENICITY AND FOR THEIR ABILITY TO LOCALIZE TO B16 CELLS IN VIVO. FINALLY, APPROPRIATE CONJUGATES WILL BE USED FOR IN SITU MANIPULATION OF THE IMMUNOGENICITY OF B16 CELLS. SATISFACTORY COMPLETION OF THIS RESEARCH SHOULD LEAD INTO THE DEVELOPMENT OF SINGLE- AGENT THERAPY FOR MELANOMA.
Technology keywords
Not reported